Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
onabotulinumtoxinA + anti-Parkinson's drugs
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
This intervention refers to a combination therapy regimen consisting of intramuscular (detrusor) injections of onabotulinumtoxinA (Botox) and standard oral anti-Parkinson's medications. Investigated by Zhujiang Hospital, this approach is specifically aimed at treating overactive bladder (OAB) symptoms in patients with Parkinson's disease. OnabotulinumtoxinA is a neurotoxin that cleaves SNAP-25, a protein essential for the docking and release of acetylcholine from presynaptic vesicles. By inhibiting acetylcholine release at the neuromuscular junction of the bladder detrusor muscle, it induces temporary muscle relaxation and reduces the urgency and frequency associated with OAB. The oral anti-Parkinson's component typically includes dopamine precursors (like levodopa) or dopamine agonists, which are used to manage the primary motor symptoms of the underlying neurodegenerative disease.
- Brand names
- Botox
- Other names
- Botulinum Toxin Type ABTX-AOnabotulinumtoxinA
02
Targets
SNAP25 (Synaptosome-associated protein 25)
Beyond the preview
Go deeper on onabotulinumtoxinA + anti-Parkinson's drugs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on onabotulinumtoxinA + anti-Parkinson's drugs.